Immunofixation (Quantitative)

Cancer

Report in 72Hrs

At Home

No Fasting Required

Details

Commonly used for diagnosing plasma cell disorders like multiple myeloma and Waldenström macroglobulinemia

₹8,950₹11,300

21% OFF

Immunofixation (Quantitative) - Comprehensive Medical Test Guide

Why is it done?
- Test Purpose: Quantitative immunofixation is a specialized serum protein electrophoresis technique that identifies and measures specific immunoglobulin (antibody) types and light chains. It detects monoclonal proteins (M-proteins) produced by abnormal plasma cells and precisely quantifies their concentration in blood serum.
- Primary Indications: Diagnosis and monitoring of monoclonal gammopathies including multiple myeloma, Waldenström macroglobulinemia, light chain disease, and primary amyloidosis
- Detection of Abnormal Proteins: Identifies monoclonal immunoglobulins (IgG, IgA, IgM, IgD, IgE) and free light chains (kappa or lambda) that indicate plasma cell malignancies or disorders
- Typical Timing: Performed when abnormal serum protein spike is detected on routine electrophoresis, during initial workup for suspected hematologic malignancy, and regularly for disease monitoring and treatment response assessment in confirmed monoclonal gammopathy cases
- Clinical Context: Often performed as reflex test following abnormal serum protein electrophoresis results or when clinical suspicion for plasma cell dyscrasias is high based on symptoms and laboratory findings
Normal Range
- Normal/Negative Results: No monoclonal protein detected (negative); presence of normal polyclonal immunoglobulins only
- Normal Immunoglobulin Ranges (approximate): IgG: 700-1,600 mg/dL | IgA: 70-400 mg/dL | IgM: 40-230 mg/dL | IgD: 0-8 mg/dL | IgE: 0-0.05 mg/dL
- Normal Free Light Chain Ratios: Kappa/Lambda ratio: 0.26-1.65; both types normally present in balanced proportions (polyclonal)
- Units of Measurement: Milligrams per deciliter (mg/dL) or grams per deciliter (g/dL); percentages of total immunoglobulins; qualitative identification of heavy and light chain types
- Interpretation of Results: Negative/Normal = No monoclonal protein spike (absent M-protein); Positive/Abnormal = Presence of distinct monoclonal spike indicating abnormal single clone of plasma cells; quantity determined by height and area of spike on immunofixation pattern
Interpretation
- Monoclonal Protein Identified: Single immunoglobulin type detected (e.g., IgG-kappa or IgA-lambda) indicates clonal proliferation of plasma cells; quantity reported as g/dL or percentage of total protein; suggests monoclonal gammopathy, multiple myeloma, Waldenström macroglobulinemia, or light chain disease
- Quantitative Values and Significance: <3 g/dL: May indicate monoclonal gammopathy of undetermined significance (MGUS), smoldering myeloma, or early disease | 3-7 g/dL: Moderate disease burden, typical in symptomatic myeloma | >7 g/dL: Significant disease burden, often associated with active myeloma and organ dysfunction
- Type-Specific Interpretation: IgG-kappa/lambda (most common in myeloma) | IgA (associated with higher renal involvement risk) | IgM (characteristic of Waldenström macroglobulinemia) | Free light chains only (light chain disease; higher nephrotoxicity risk) | Biclonal or triclonal pattern (rare; indicates multiple clones)
- No Monoclonal Protein Detected: Polyclonal pattern only (normal); excludes monoclonal gammopathy; however, approximately 1% of multiple myeloma cases are non-secretory (produce no detectable M-protein); in such cases, serum-free light chain assay and bone marrow biopsy become critical
- Serial Monitoring Interpretation: Increasing M-protein levels indicate disease progression or treatment failure | Decreasing levels suggest therapeutic response | Stable levels in monitored patients indicate disease stability; changes >25% are generally considered clinically significant
- Factors Affecting Results: Hemolysis may interfere with results | Sample timing affects accuracy (morning fasting samples preferred) | Immunosuppressive therapy can suppress M-protein production | Hydration status affects serum protein concentrations | Acute infections may cause temporary polyclonal immune response masking monoclonal spike
- Clinical Significance Patterns: Suppressed normal immunoglobulins with elevated monoclonal protein = poor prognostic indicator; paradoxically low M-protein with severe renal dysfunction = indicator of light chain disease; complete response defined as undetectable M-protein on immunofixation
Associated Organs
- Primary Organ Systems Involved: Bone marrow (where abnormal plasma cells originate and proliferate) | Blood/vascular system (monoclonal proteins circulate in serum) | Lymphoid tissues (lymph nodes, spleen may be involved in lymphoproliferative disorders)
- Commonly Associated Diseases and Conditions: Multiple myeloma (most common malignancy with M-protein) | Monoclonal gammopathy of undetermined significance (MGUS) | Waldenström macroglobulinemia | Light chain disease | Primary amyloidosis (AL amyloidosis) | Heavy chain disease | Smoldering multiple myeloma
- End-Organ Damage Risks: Renal dysfunction (most common; caused by light chain nephropathy, cast nephropathy, or monoclonal immunoglobulin deposition disease) | Bone disease (lytic lesions, osteoporosis, hypercalcemia from osteoclast activation) | Nervous system involvement (amyloid neuropathy, central nervous system infiltration) | Hepatic involvement (rare but possible) | Cardiac complications (amyloid cardiomyopathy)
- Complication Spectrum: Acute kidney injury requiring dialysis | Severe infections due to immunosuppression from abnormal plasma cell proliferation | Hyperviscosity syndrome (particularly IgM, IgG3, IgA) causing neurologic and bleeding complications | Cryoglobulinemia | Tumor lysis syndrome during treatment initiation
- Diagnostic Utility for Specific Conditions: Definitive diagnosis of multiple myeloma when combined with bone marrow biopsy and imaging | Differentiation between MGUS (low disease burden) and active myeloma | Identification of disease type guiding treatment selection | Monitoring for disease progression in asymptomatic patients
Follow-up Tests
- Immediate Follow-up Tests When Monoclonal Protein Detected: Serum-free light chain assay (quantifies kappa and lambda chains; establishes baseline ratio) | 24-hour urine electrophoresis (detects Bence Jones proteinuria) | Bone marrow biopsy with flow cytometry (determines plasma cell percentage and establishes diagnosis) | Serum beta-2 microglobulin (prognostic indicator) | Serum calcium and creatinine (assess for myeloma defining events)
- Imaging Studies: Skeletal survey or low-dose whole-body CT (assess for lytic bone lesions) | MRI of spine (evaluates for spinal involvement or plasmacytomas) | PET-CT (when conventional imaging inconclusive; prognostic significance)
- Organ Function Assessment: Comprehensive metabolic panel (electrolytes, creatinine, calcium, albumin) | Urinalysis with microscopy (detect proteinuria, casts) | 24-hour urine protein (quantify proteinuria burden) | Echocardiography (if amyloidosis suspected) | Nerve conduction studies (if neuropathy suspected)
- Serial Monitoring in Confirmed Monoclonal Gammopathy: MGUS: Repeat quantitative immunofixation every 6-12 months for 2 years, then annually or as clinically indicated | Active myeloma on treatment: Every 4-8 weeks during induction therapy; every 8-12 weeks during maintenance therapy | Stable disease: Every 8-12 weeks to monitor for progression
- Complementary Tests for Disease Characterization: Immunophenotypic flow cytometry (characterizes abnormal plasma cell population) | Cytogenetics and FISH (prognostic and therapeutic decision-making) | LDH level (prognostic indicator) | Complete blood count (cytopenias, anemia assessment) | Coagulation studies (if cryoglobulinemia or hyperviscosity suspected)
- Treatment Response Monitoring Tests: Repeat quantitative immunofixation (primary response marker; defines response categories) | Serum-free light chain ratio (alternative marker when M-protein <1 g/dL) | Minimal residual disease (MRD) assessment by flow cytometry or molecular testing (increasingly used for risk stratification and prognostication)
Fasting Required?
- Fasting Requirement: NO fasting is specifically required for quantitative immunofixation
- Sample Collection Considerations: Morning samples preferred (more consistent due to circadian variations in protein levels) | Early collection helps ensure processing same day | Serum sample required (not plasma) | Typically 5-10 mL venipuncture collection
- Medications - No Restrictions: Continue all routine medications as prescribed (immunosuppressives, biologics, chemotherapy should not be held) | Myeloma-directed therapy should continue unless specifically instructed otherwise by treating physician | Prophylactic medications (anticoagulants, bisphosphonates, antimicrobials) do not interfere with test results
- Patient Preparation Requirements: No special preparation needed | Maintain normal hydration status (dehydration can falsely elevate protein levels) | Avoid extreme physical exertion immediately before collection (may transiently affect protein levels) | Inform phlebotomist of any acute illness or recent transfusions
- Special Circumstances: Recent blood transfusion may affect results (ideally sample 24-48 hours after transfusion) | Plasmapheresis - timing of sample collection relative to procedure affects M-protein quantification | Recent contrast administration does not interfere | If collecting 24-hour urine simultaneously, ensure adequate hydration throughout collection period

How our test process works!